Report Name: C. R. Bard Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy EvaluationR. Bard Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
R. Bard – Business Description:
R. Bard is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company sells its products worldwide to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It has operations in the US, Europe, Japan and other regions. The company categorizes its products into four business divisions (product categories): vascular; oncology; urology; and surgical specialties. The company also has business under its other products group. Bard’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. Its minimally invasive vascular product line includes percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories. Product line also includes: valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters. As of December 31, 2016, vascular products recorded revenues of $1,014.9 million, an increase of 4.6% over FY2015. Bard’s oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. The company’s specialty vascular access products are used primarily for chemotherapy. Oncology products recorded revenues of $1,012.1 million in FY2016, an increase of 8% over FY2015. Bard’s urology products include basic urology drainage products; fecal and urinary continence products; and urological specialty products and targeted temperature management products. The Foley catheter is one of the most important products in the urology field. Other urology products include brachytherapy devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; and surgical slings and pelvic floor repair products for women’s health. The company also markets the proprietary line of StatLock catheter stabilization devices, which are used primarily to secure peripheral intravenous catheters, thereby reducing restarts and other complications. These devices are also used to secure many other types of catheters sold by Bard and other companies, including Foley catheters. In addition, the company markets the Arctic Sun system with proprietary ArcticGel pads providing therapy for patients requiring Targeted Temperature Management. Urology products recorded revenues of $951.8 million in FY2016, an increase of 12.6% over FY2015. The company’s surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs in addition to hemostats and surgical sealants. The company’s soft tissue repair products consist of hernia repair grafts, including permanent synthetic and bioresorbable synthetic products, natural-tissue configurations, and hernia fixation devices. Surgical specialties products recorded revenues of $637.3 million in FY2016, an increase of 11.4% over FY2015. The other product group of the company includes irrigation, wound drainage and certain original equipment manufacturers’ products. Other products recorded revenues of $97.9 million in FY2016, an increase of 7% compared to FY2015. Geographically, the US, Bard’s largest geographic market, accounted for 68.9% of the total revenues in FY2016. Revenues from the US reached $2,559.5 million in FY2016, an increase of 7.6% over FY2015. Asia accounted for 13.2% of the total revenues in FY2016. Revenues from Asia reached $489.4 million in FY2016, an increase of 25.9% compared to FY2015. Europe accounted for 12% of the total revenues in FY2016. Revenues from Europe reached $446.4 million in FY2016, an increase of 1.6% compared to FY2015. Other regions accounted for 5.9% of the total revenues in FY2016. Revenues from other regions reached $218.7 million in FY2016, an increase of 4.4% over FY2015.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757